Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

To get accurate and reliable patency status in Saudi Arabia and Middle East countries

— Director, business development, Saudi Arabia

To have a global perspective of drug product patents

— Generic drug product company R&D manager, Spain

To see which oncology / CNS drug patents face expiration in Brazil

— Business development coordinator, pharmaceutical lab, USA

To get Information about drug patent expiry for drugs approved in Germany and UK since 1990

— Economist, Germany

To find manufacturing sources for registration and sales in Sweden

— Pharmaceutical whoesaler, Sweden

Generated: May 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,623,826

« Back to Dashboard

Which drugs does patent 8,623,826 protect, and when does it expire?


Patent 8,623,826 protects AKYNZEO and is included in one NDA.

This patent has forty-eight patent family members in thirty-six countries.

Summary for Patent: 8,623,826

Title:Compositions and methods for treating centrally mediated nausea and vomiting
Abstract: Provided are methods for treating nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery, comprising the co-administration of netupitant, palonosetron and dexamethasone.
Inventor(s): Trento; Fabio (Como, IT), Cantoreggi; Sergio (Cagiallo, CH), Rossi; Giorgia (Como, IT), Cannella; Roberta (Varese, IT), Bonadeo; Daniele (Varese, IT)
Assignee: Helsinn Healthcare S.A. (Lugano/Pazallo, CH)
Application Number:13/077,462
Patent Claim Types:
see list of patent claims		Use; Delivery;

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Helsinn Hlthcare
AKYNZEO
netupitant; palonosetron hydrochloride
CAPSULE;ORAL205718-001Oct 10, 2014RXYesYes8,623,826► Subscribe PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,623,826

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,271,975Compositions and methods for treating centrally mediated nausea and vomiting► Subscribe
8,951,969Compositions and methods for treating centrally mediated nausea and vomiting► Subscribe
9,186,357Compositions and methods for treating centrally mediated nausea and vomiting► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,623,826

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico2012005347► Subscribe
Morocco33810► Subscribe
Lithuania2722045► Subscribe
South Korea101615108► Subscribe
South Korea20120101456► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

To get information on ANDA & Paragraph IV challenges

— Global head business team (API & generics), Netherlands

To obtain a list of all currently off-patent approved small molecule therapeutics or those that will come off patent in the next 5 years

— Licensing / business development, Saudi Arabia

To study crossover potential for veterinary medicine

— Chief medical officer, USA

To identify Paragraph IV challenge opportunities and for product portfolio development

— Business development, China

For information of pharmaceutical patent expiry dates

— Patent attorney, USA

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Related Products from thinkBiotech
Links

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot